IL17A and psoriasis: In particular, in the real-life experience reported by Fougerousse et al. with the aim of investigating the effectiveness and short-term (16 weeks) tolerance of guselkumab for psoriasis under real-life conditions, only 39 out of 180 subjects had previously failed anti-IL17 treatment [24].